Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 17 Show results per page	View Search Criteria \| Help With Results

Last Modified: 11/1/2001 First Published: 5/1/1999


1.		Phase III Randomized Study of Zoledronate Versus Pamidronate in Patients With Cancer-Related Bone Lesions Due to Multiple Myeloma or Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				18 and over				Pharmaceutical / Industry				NOVARTIS-4244603010 UCLA-9911015

Last Modified: 7/21/2008 First Published: 4/1/2002


2.		Phase III Randomized Study of Dexamethasone With or Without Thalidomide in Patients With Newly Diagnosed Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				NCI				E-E1A00 NCT00033332, E1A00

Last Modified: 12/1/1989


3.		Phase III Study of the Effect of Bisphosphonate APD on Morbidity Caused by Enhanced Bone Resorption in Stage II/III Multiple Myeloma (Summary Last Modified 12/89)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				20 to 75								DUT-KWF-CKVO-8414 DUT-IKA-851

Last Modified: 3/1/1990


4.		Phase III Randomized, Double-Blind Study of Gallium Nitrate vs Disodium Pamidronate (APD) in Patients with Cancer-Related Hypercalcemia (Summary Last Modified 03/90)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Completed				18 and over				NCI				FRE-IGR-T89-0069 NCI-T89-0069A, T89-0069

Last Modified: 11/12/2007


5.		Phase III Randomized, Placebo-Controlled Study of Pamidronate by 4-Hour Infusion for the Prevention of Skeletal-Related Episodes in Multiple Myeloma Patients with Osteolytic Lesions

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Closed				18 and over								CG-AREDIA-12 NCI-V92-0039

Last Modified: 11/12/2007


6.		Phase III Randomized Placebo-Controlled Study of Oral Pamidronate in Patients with Newly Diagnosed Bone Metastases from Breast Cancer (Summary Last Modified 09/93)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				over 18								EORTC-10924

Last Modified: 11/12/2007 First Published: 5/23/2007


7.		Phase I/II Pilot Study of Samarium Sm 153 Lexidronam Pentasodium in Combination With Zoledronic Acid or Pamidronate Disodium in Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Supportive care, Treatment				Closed				18 and over				NCI				MAYO-MC048B MAYO-IRB-261-05, MC048B, NCT00482378

Last Modified: 10/20/2007


8.		Phase II Randomized, Double-Blind Study of Zoledronate vs Pamidronate for the Prevention of Skeletal-Related Episodes in Multiple Myeloma or Breast Cancer Patients with Osteolytic Bone Metastases (Summary Last Modified 11/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care, Treatment				Closed				18 and over				Pharmaceutical / Industry				UCLA-HSPC-960628101 NCI-V96-0975

Last Modified: 12/1/1999 First Published: 8/1/1998


9.		Phase II Randomized Study of Zoledronate or Pamidronate in Patients with Tumor Induced Hypercalcemia (Summary Last Modified 12/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care				Closed				18 and over				Pharmaceutical / Industry				NOVARTIS-4244604037 CGP-42446, NCI-V98-1413

Last Modified: 2/15/2005 First Published: 10/1/1999


10.		Phase II Study of Sequential High-Dose Melphalan, Busulfan, and Cyclophosphamide Followed By Peripheral Blood Stem Cell Rescue, Interferon alfa, Pamidronate, and Thalidomide in Patients With Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				65 and under				NCI				CHNMC-IRB-99021 NCI-G99-1583, NCT00004088

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute